SCHEDULE 13G/A: Freebird Partners LP Amends Stake in Eterna Therapeutics, Maintaining 9.99% Beneficial Ownership

Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.99% of Eterna Therapeutics Inc.'s common stock as of October 29, 2024.

Summary

• The Reporting Persons (Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff) collectively beneficially own 5,136,696 shares of Eterna Therapeutics Inc. common stock.
• This ownership represents 9.99% of the Issuer's total outstanding common stock.
• The beneficially owned shares include 5,136,686 shares directly held by Freebird Partners LP and 10 shares issuable upon the exercise of a pre-funded common stock purchase warrant.
• A 'Blocker' provision in the warrant prevents the Reporting Persons from exercising it to the extent their beneficial ownership would exceed 9.99% of outstanding common stock, resulting in 1,008,990 shares currently excluded from exercise.
• The percentage of ownership is calculated based on an aggregate of 51,374,723 shares of Eterna Therapeutics Inc. common stock outstanding, derived from 51,374,713 shares reported in the Issuer's Form 10-Q filed on November 12, 2024, plus the 10 warrant shares.
• This filing is Amendment No. 3 to the Schedule 13G, indicating an update to previously reported beneficial ownership.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership, which is generally neutral. The maintenance of a significant stake by an institutional investor can be seen as mildly positive, indicating continued confidence, but it contains no new operational or financial news about the company itself.

Positives

• A significant institutional investor (Freebird Partners LP) maintains a substantial stake, indicating continued confidence in Eterna Therapeutics Inc.
• The 'Blocker' provision in the warrant limits the investor's ownership to just under 10%, which can be seen as a stable, non-activist position, potentially reducing concerns about hostile takeovers or disruptive influence.

Risks

• The 'Blocker' provision on the warrant limits the ability of Freebird Partners to increase their stake beyond 9.99% through warrant exercise, potentially capping their upside from this specific instrument if the stock price significantly increases.

Future Outlook

The document is a disclosure of beneficial ownership and does not provide forward-looking statements or guidance regarding Eterna Therapeutics Inc.'s future performance or strategic direction. It primarily details the current ownership structure of Freebird Partners LP and related entities.

Management Comments

• The Reporting Persons (Freebird Partners LP, Freebird Investments LLC, and Curtis Huff) certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake in a publicly traded company. It indicates that a specific investment group holds a substantial, but non-controlling, position in Eterna Therapeutics Inc. without suggesting any broader industry trends or competitive shifts. The presence of a 'Blocker' provision in the warrant is a common mechanism to prevent triggering certain regulatory thresholds or activist investor classifications.

Comparison to Industry Standards

• This Schedule 13G filing is a routine disclosure for investors acquiring more than 5% of a company's shares, indicating a passive investment intent.
• The 9.99% ownership level is just below the 10% threshold that often triggers additional reporting requirements or insider trading rules for beneficial owners.
• The use of a 'Blocker' provision in warrants is a standard practice in capital raises to ensure compliance with beneficial ownership limits and avoid triggering unwanted regulatory or corporate governance implications, such as those related to Section 16 of the Exchange Act.
• No specific comparable companies or projects are mentioned in this filing, as it focuses solely on the ownership stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake and passive investment intent.

Key Dates

Recommendation

Keywords

Eterna Therapeutics Inc., Freebird Partners LP, Schedule 13G, Beneficial Ownership, Common Stock, Warrant, SEC Filing, Institutional Investor, Equity Stake, Shareholder Disclosure